Monthly Archives: September 2015

Real World Evidence Making Headlines

Click here to subscribe to SVMPharma’s RWE updates

Latest Updates

Real-world data (RWD) overcomes the COVID-19 restrictions placed on entering hospitals
COVID-19 pandemic catalyses real-world oncology data uptake
Real-world evidence (RWE) market worth over £1bn by 2023
Adjuvant immunotherapy conferred a 93% survival at 1 year for patients with resectable melanoma at the highest risk of relapse
NICE funding impacts treatment sequencing patterns in chronic myeloid leukaemia (CML)

Quick Links

Real World Evidence
Global Real World Evidence
Additional Services
Privacy Policy
Contact Us

About SVMPharma

SVMPharma is a bespoke strategic consultancy based in Hampshire UK, specialising in Real World Evidence (RWE) for the pharmaceutical and healthcare industries. At SVMPharma we also cover Global RWE, Patient Experience, Big Data Analytics and Influence Mapping alongside Additional Services. Find further information and read our latest articles in the Resource Centre.

+44 (0)1252 964650

Quick Links

Real World Evidence
Global Real World Evidence
Additional Services
Privacy Policy
Contact Us

Twitter

Tweets by @SVMPharma

Latest News

Researchers say hydroxychloroquine could still prevent COVID-19 August 7, 2020
EU approves new indication for Novartis’ Xolair August 7, 2020
Second COVID-19 peak in the UK can be avoided with testing and tracing, study finds August 7, 2020
GSK’s anti-BCMA drug Blenrep wins US approval August 7, 2020
AZ’s Fasenra study confirms robust efficacy in eosinophilic asthma August 6, 2020

Privacy Policy
Website Disclaimer
Sitemap